BioGrad announces a £3 million investment in a new Yorkshire office, signaling national expansion.
- The Liverpool-based firm opens a research and teaching site in York to strengthen its UK presence.
- A nationwide clinical trial is anticipated to commence in early 2025, led by the York team.
- Previously established sites include Birmingham, Newcastle, and London, supporting BioGrad’s expansive growth.
- Local authorities play a crucial role in facilitating BioGrad’s strategic expansion into Yorkshire.
BioGrad, a prominent laboratory technology firm, has made a significant leap in its national presence by announcing a £3 million investment in opening a new office in Yorkshire. This move is part of BioGrad’s ongoing national expansion strategy, aimed at positioning itself at the forefront of science and healthcare, especially in regenerative medicine and clinical research.
The establishment of a research and teaching site in York not only extends BioGrad’s geographic footprint but also enhances its capability to lead groundbreaking research. BioGrad plans to spearhead a nationwide clinical trial from this new site, with the trial anticipated to begin in early 2025. This aligns with BioGrad’s mission to innovate within the clinical research landscape.
Since 2022, BioGrad has strategically opened facilities in Birmingham, Newcastle, and London. Added to these efforts is their purpose-built headquarters and clinical research center at Wavertree Technology Park in Liverpool, a hub of innovation and learning. With approximately 150 employees, BioGrad’s growth is further bolstered by its educational arm, BioGrad Education, which achieved recognition as the first North West company to secure investment from the £660 million Northern Powerhouse Investment Fund II.
Dr. Natalie Kenny, CEO of BioGrad, has highlighted the exceptional support received from local officials, particularly in York and North Yorkshire, citing it was instrumental in making York the preferred location for their new site. This includes the vital assistance from individuals like Sophie Hartley and Christine Hogan, who contributed significantly to this strategic choice. Their collaboration showcases the strength of the region’s infrastructure, including its world-class NHS Trust and academic institutions, making York an ideal setting for BioGrad’s operations.
The Mayor of York and North Yorkshire, David Skaith, has expressed enthusiasm over BioGrad’s investment, underscoring the creation of high-quality, skilled job opportunities, which is crucial to boosting the local economy. Such initiatives are poised to leverage the demographic strengths and research capabilities of the region, potentially establishing York as a leader in global healthcare.
BioGrad’s strategic investment in York sets the stage for advancements in clinical research and job creation, strengthening its national footprint.
